Leading Edge Genomic Services & Solutions

Novogene Europe Relocates its Sequencing Centre to Cambridge Science Park

CAMBRIDGE, UK, Oct 17, 2019 – Novogene Europe has upgraded and relocated its first European Sequencing Centre to TusPark UK’s new Bio-Innovation Centre in the Cambridge Science Park. The grand opening ceremony of Novogene’s new facility was held at 2 pm, 11th October 2019.

The move to the Bio-Innovation Centre has enabled Novogene’s Cambridge Sequencing Centre to expand its operation and continue to provide unsurpassed turnaround times and guaranteed data quality. With a professional team recruited from all over the world, the Centre offers leading-edge Next Generation Sequencing (NGS) services and solutions for all types of projects. The lab is now equipped with a variety of platforms, including an automatic system for library preparation, multiple NovaSeq 6000s and High Performance Computing Clusters. Novogene Cambridge Sequencing Centre is now capable of performing more than 280,000 human WGS analysis per year.

Novogene is a leading provider of genomic services and solutions with cutting edge NGS and bioinformatics expertise, and more advanced sequencing capacity in the world. The Novogene Europe subsidiary was established in 2014 to address the European market for NGS and expand Novogene’s business in Europe. Novogene Europe now provides leading edge services and solutions to customers in over 30 countries in Europe.

Novogene’s comprehensive service offering at its Cambridge Sequencing Centre includes human genome sequencing, plant and animal genome sequencing, transcriptome sequencing, metagenome sequencing, and lanes sequencing. Additional services are planned for the near future enabling Novogene Europe to provide even more optimized solutions for clients based on their research goals.

Ms. Tingting Zhou, the general manager of Novogene Europe, said, “The relocation of Novogene Cambridge Sequencing Centre helps us to improve our services, which is a significant development milestone of Novogene Europe. This means that we can deliver higher levels of NGS services and help our clients to solve the practical problems in their research. Our customers encouraged us to expand our services as we have always been trying to maximize the benefits for our customers. I also believe that our Cambridge Sequencing Centre will continue to thrive.”

“We are delighted to welcome Novogene to the Bio-Innovation Centre,” said Dr. David Chaplin, TusPark UK’s General Manager of the Bio-Innovation Centre. “Emerging technologies like NGS play critical roles in human health, environmental protection, plant and animal breeding and microbial remediation. The relocation of Novogene Cambridge Sequencing Centre is a fantastic new addition to the Cambridge Science Park. It’s our pleasure to establish a long-term relationship and grow together with Novogene.”

About Novogene Europe

Novogene Europe, established in 2014, is a Subsidiary of Novogene. It makes significant contributions to advancing human heath, agriculture, and environmental protection. Over 300 scientific research institutes and biotechnology companies in Europe rely on the powerful technologies and services of Novogene Europe. With leading-edge platforms, well developed bioinformatics pipelines, extensive experience in NGS, and the support from skilled employees, Novogene Europe has become the most competitive NGS provider in Europe.

About Cambridge Science Park

The Cambridge Science Park was established in 1970 by Trinity College – the largest of the colleges of the University of Cambridge. Trinity owns the freehold of the Cambridge Science Park which comprises 1.7 million sq ft of high technology and laboratory buildings set in 152 acres of mature parkland. Today, the Park is home to 7000 people at over 130 companies ranging from exciting start-ups to some of the world’s leading technology businesses.

Contact:

Ms. Tingting Zhou
General Manager
Novogene Europe
tingting.zhou@novogene-europe.com

Dr. Yan Wang
Tuspark UK
Operations Manager
yan.wang@tuspark.co.uk

Year-End Promotion

RNA sequencing promotion
Service package: 6G,12G,15G
Term: library preparation + sequencing + quantification analysis
Minimum 18 samples,
Offer starts from 149 USD/sample
Quantification analysis only
Whole exome sequencing promotion
Service package: 12G,24G
Term: library preparation + sequencing + analysis (optional)
Capture kit: Agilent SureSelect Human All Exon V6
Only applicable for non-FFPE human samples
Minimum 18 samples,
Offer starts from 299 USD/sample
Lane sequencing promotion on NovaSeq 6000
Access all data at an unexpected low price per Gb
Term: this price could not be applied to WGBS, PCR product library
and 10×genomics single cell RNA library
Free Shipment for Q4
Terms and conditions:

Promotion will be valid if payment is proceeded before 15th December or sample arrival before 30th November, 2019
Novogene Europe reserves the rights of final interpretation.Terms and conditions are subject to change at any time without notice* Free Shipment for the first 100 projects is available in Cambridge only.For more details and other promotion, please contact your local account manager or europe@novogene.com
About Novogene Cambridge Sequencing Centre

Novogene Cambridge Sequencing Centre relocated to Cambridge Science Park in August, 2019. This relocation promoted the expansion of laboratory and workforce, the increase of service diversity and throughput, and the shortening of turnaround time. Currently, we have more than 30 employees working in the lab. The center is equipped with NovaSeq 6000 sequencer and associated supporting facilities, providing a solid guarantee for future business development of Novogene Europe.

  • NOVOGENE (UK) COMPANY LTD.
  • 25 Cambridge Science Park
  • Milton Road
  • Cambridge, CB4 0FW
  • United Kingdom
  • T:+44(0)1223 628750
  • E:europe@novogene.com
  • W:en.novogene.com

Chipscreen and Novogene enter a strategic partnership for companion diagnostics development

Chipscreen Biosciences Co., Ltd. (Chipscreen, Stock Symbol: 688321. SH) and Novogene Co., Ltd. (Novogene) recently announced a strategic partnership for companion diagnostics (CDx) development. Under the agreement, Novogene will develop a CDx for Chipscreen’s anti-tumor drug candidate Chiauranib (CS2164), and will provide molecular testing services during Chipscreen’s clinical trials on Chiauranib.

Chiauranib is a multi-kinase inhibitor designed and developed by Chipscreen to target several novel molecules in three signaling pathways. Its anti-tumor effects stem from the simultaneous inhibition of angiogenesis and mitosis as well as the modification of the tumor microenvironment. According to the agreement, Chipscreen will leverage Novogene’s professional CDx development team and its CAP-accredited lab in Tianjin, China, to accelerate the clinical development of Chiauranib. “The collaboration between Chipscreen and Novogene will help select the right patients for the clinical development of Chiauranib in several tumor types, including ovarian cancer, small cell lung cancer, liver cancer, and non-Hodgkin’s lymphoma.” Said Dr. Zhiqiang Ning, Executive Vice President of Chipscreen, “In the US and many European countries, the co-development of innovative therapeutics and companion diagnostics is already a common practice because it has proven to increase the efficiency and success rate of drug development. We really hope our partnership with Novogene will help implement this idea and practice in China to benefit more patients faster.”

CDx not only increases the efficiency and success rate of drug development, but also makes treatment more personalized and effective. This is particularly important in the development of targeted therapies and immunotherapies in oncology. “Novogene offers a one-stop-shop molecular CDx development platform, has the experience of successfully developing and registering oncology in vitro diagnostics in China and operates a diagnostics sales network that covers the entire domestic market. We are thus perfectly positioned to provide pharma partners with comprehensive, value-added CDx services.” Said Dr. Jeff Cheng, Chief Scientific Officer of Novogene, “This partnership between two companies that are each leading player in their own field is an exciting joint effort on the orchestrated development, registration and commercialization of an innovative targeted therapy and its CDx in China.”

About Chipscreen

In 2001, Chipscreen Biosciences was founded in Shenzhen, specializing in the research and development of original small molecule drugs. With the self-created “integrated drug discovery and early evaluation platform based on chemical genetics” as its core competitiveness, Chipscreen Biosciences has now become one of China’s leading innovative drug enterprises, forming a modern biomedicine group company in Shenzhen, as its headquarters / research and development center / GMP production base, Chengdu, as a regional headquarter / research and development center / GMP production base, Beijing clinical research center and Shanghai commercial center. At present, the company has developed a number of original new drug product lines for tumors, diabetes, and endocrine and autoimmune diseases. In December 2014, the original anti-tumor new drug Chidamide was approved by the China Food and Drug Administration for marketing. Shenzhen Chipscreen Biosciences Co., Ltd. (Stock Symbol: 688321.SH) has been listed on the SSE STAR Market on August 12, 2019.

About Novogene

Founded in March 2011 in Beijing Zhonguangcun Life Science Park, Novogene specializes in the application of cutting-edge molecular biology technologies and high-performance computing in life science research and human health. Currently providing services to clients in more 60 countries and 6 continents, Novogene has become a global leader in the field of genomic sequencing and bioinformatics services.
With a deep understanding of the drug R&D process, rich project management experience and a strong commitment to data quality, Novogene provides fully integrated services for preclinical, translational, clinical and diagnostic R&D needs from pharmaceutical companies across the world in our strategically located CAP-accredited and CLIA-certified labs across the globe.